Contents:

1 Executive Summary 2 Cancer Highlights 3 Methodology 4 Table of Contents 4.1 List of Boxes 4.2 List of Tables 5 Introduction 5.1 Disease Definitions 5.2 Etiology & Pathophysiology 5.3 Epidemiology 5.4 Prognosis 6 Current Treatment Strategies 6.1 Localized Disease 6.1.1 Locally Advanced Prostate Cancer 6.2 Metastatic Prostate Cancer 6.2.1 Hormone-Sensitive Metastatic Prostate Cancer 6.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer 7 Progress in Current Treatment Strategies 7.1 Long-Term Follow-up Data not yet Been Published 7.2 Significant Reduced Risk of Distant Metastases 7.3 Adverse Events 7.4 No Difference in Overall Survival 7.5 Cross-over Design an Optimal Option? 7.6 Death due to Liver Failure 7.7 Survival Benefit 7.8 Subdermal Implant 7.9 No FDA Approval 7.10 No Improvement in 5-year Disease-Free Survival 7.11 Effective Secondary Hormonal Therapy? 7.12 Synery in Combination 8 Key Therapeutic Strategies for Future Therapies 8.1 Therapeutic Type, Targets & Mechanisms 9 Competitive Landscape in Drug Development: The Late Stage Pipeline 9.1 Reduced Prostate Cancer Risk 9.2 High Activity in Metastatic AIPC Patients 9.3 Absence of Severe Toxicities 9.4 Waiting for Data 9.5 Probability of Regulatory Approval? 9.6 Co-development and License Agreement 9.7 Improves Predicted Survival? 9.8 Slow Progress & Development Partners 9.9 Exclusive License Agreement 10 Current Drug Development: The Early Stage Pipeline 10.1 New Data? 10.2 Terminated Study 10.3 More Than 50% PSA decline 10.4 Safety and Tolerability 10.5 Terminated 10.6 Marker of Drug Effect 10.7 Preliminary Results for a Tyrosine Kinase Inhibitor 10.8 No Activity in Monotherapy 10.9 Dramatic Disappearance of Bone Metastatic Lesions 10.10 PSA Response - Anthracycline 11 Disclaimer 11.1 Liability 11.2 Completeness 12 Drug Index 13 Company Index 4.1 List of Boxes Box 1: The Eastern Cooperative Oncology Group Study Box 2: Southwest Oncology Group Study 99-16 Design Box 3: TAX 327 Study Design Box 4: Quick Facts - Toremifene Box 5: Quick Facts - Bevacizumab Box 6: Quick Facts - Genasense Box 7: Quick Facts - R-flurbiprofen Box 8: Quick Facts - Provenge Box 9: Quick Facts - Satraplatin Box 10: Quick Facts - GVAX Box 11: Quick Facts - Exisulind Box 12: Quick Facts - Vapreotide Box 13: Quick Facts - DCVax 4.2 List of Tables Table 1: The TNM System Table 2: Lifestyle factors Table 3: Historical Summary of Clinical Studies on Patients with Late Stage Disease Table 4: Short Facts Abarelix Table 5: Short Facts Bicalutamide Table 6: Short Facts Carboplatin Table 7: Short Facts Docetaxel Table 8: Short Facts Mitoxantrone Table 9: Short Facts Flutamide Table 10: Short Facts Goserelin Table 11: Short Facts Histrelin Table 12: Short Facts Lanreotide Table 13: Short Facts Leuprolide Table 14: Short Facts Nilutamide Table 15: Short Facts Estramustine Table 16: Summary of Recent Clinical Studies on Patients with Late Stage Disease Table 17: Ongoing Late Stage Clinical Studies Table 18: Cancer Immunotherapy Strategies Table 19: Near Term Progress Toremifene Table 20: Near Term Progress Bevacizumab Table 21: Near Term Progress Oblimersen Table 22: Near Term Progress R-flurbiprofen Table 23: Near Term Progress APC8015 Table 24: Near Term Progress Satraplatin Table 25: Near Term Progress GVAX Table 26: Near Term Progress Exisulind Table 27: Summary of Prostate Cancer Late Stage Pipeline Table 28: Paclitaxel Table 29: Epothilone Table 30: Ixabepilone Table 31: PTK/ZK Table 32: Arsenic trioxide Table 33: Retinoic Acid Table 34: Imatinib Table 35: Bortezomib Table 36: Sorafenib Table 37: Doxorubicin Table 38: Summary of Prostate Cancer Early Stage Pipeline

Companies Mentioned

Companies Mentioned Include: - Orion Pharma - Genentech - Genta - Encore Pharmaceuticals - Dendreon - Johnson Matthey - Cell Genesys - OSI Pharmaceuticals - Debiopharm - Northwest Biotherapeutics - Kosan Biosciences - Bristol-Myers Squibb - Cephalon - Antigenics - Novartis - Millennium - Bayer - Johnson & Johnson